Table 4.
Risk of site-specific cancers after syncope, by follow-up period.a
| Site | 0–6 months | >6–12 months | >12 months | 0–20 years | ||||
|---|---|---|---|---|---|---|---|---|
| Observed/expected | SIR (95% CI) | Observed/expected | SIR (95 % CI) | Observed/expected | SIR (95% CI) | Observed/expected | SIR (95% CI) | |
| Intracranial tumours | ||||||||
| Meninges | 93/8 | 11.4 (9.2–13.4) | 19/8 | 2.5 (1.5–3.9) | 157/106 | 1.5 (1.3–1.8) | 269/121 | 2.2 (2.0–2.5) |
| Brain | 231/23 | 9.99 (8.6–11.4) | 46/22 | 2.1 (1.6–2.8) | 338/284 | 1.2 (1.2–1.3) | 615/329 | 1.9 (1.7–2.0) |
| Supradiaphragmatic tumours | ||||||||
| Pharynxb | 17/7 | 2.3 (1.4–3.7) | 12/7 | 1.8 (0.9–3.1) | 182/96 | 1.9 (1.6–2.2) | 211/110 | 1.9 (1.7–2.2) |
| Lung | 366/135 | 2.7 (2.4–3.0) | 134/125 | 1.1 (0.9–1.3) | 1655/1541 | 1.1 (1.0–1.1) | 2155/1802 | 1.2 (1.2–1.3) |
| Tongue | 9/3 | 2.6 (1.2–4.9) | 7/3 | 2.2 (0.9–4.4) | 56/44 | 1.3 (1.0–1.7) | 69/48 | 1.4 (1.1–1.8) |
| Oral cavity | 13/6 | 2.1 (1.1–3.7) | 13/6 | 2.3 (1.2–3.9) | 116/71 | 1.6 (1.3–2.0) | 142/83 | 1.7 (1.4–2.0) |
| Breast | 140/114 | 1.2 (1.0–1.5) | 110/108 | 1.0 (0.8–1.2) | 1407/1424 | 1.0 (0.9–1.0) | 1657/1646 | 1.0 (1.0–1.1) |
| Infradiaphragmatic tumours | ||||||||
| Liver | 41/11 | 3.8 (2.8–5.2) | 16/10 | 1.6 (0.9–2.6) | 162/124 | 1.3 (1.1–1.5) | 219/145 | 1.5 (1.3–1.7) |
| Stomach | 60/20 | 2.9 (2.6–3.8) | 29/19 | 1.5 (1.0–2.2) | 212/220 | 1.0 (0.8–1.1) | 301/259 | 1.2 (1.0–1.3) |
| Kidney | 49/19 | 2.6 (1.9–3.5) | 24/17 | 1.4 (0.9–2.1) | 229/219 | 1.0 (0.9–1.2) | 302/256 | 1.2 (1.1–1.3) |
| Colorectalc | 308/155 | 2.0 (1.8–2.2) | 149/145 | 1.0 (0.9–1.2) | 1812/1765 | 1.0 (1.0–1.1) | 2269/2065 | 1.1 (1.1–1.6) |
| Oesophagus | 27/15 | 1.8 (1.2–2.7) | 18/14 | 1.3 (0.8–2.1) | 220/169 | 1.3 (1.1–1.5) | 265/198 | 1.3 (1.2–1.5) |
| Prostate | 228/135 | 1.7 (1.5–1.9) | 120/126 | 1.0 (0.8–1.1) | 1610/1649 | 1.0 (0.9–1.0) | 1958/1910 | 1.0 (1.0–1.1) |
| Pancreas | 48/31 | 1.6 (1.1–2.1) | 17/29 | 0.6 (0.3–0.9) | 375/361 | 1.0 (0.9–1.2) | 440/421 | 1.0 (1.0–1.2) |
| Urinary bladder | 93/69 | 1.4 (1.1–1.7) | 79/64 | 1.24 (1.0–1.6) | 787/748 | 1.1 (1.0–1.1) | 959/879 | 1.1 (1.0–1.2) |
| Haematology malignancies | ||||||||
| Non-Hodgkin lymphoma incl. multiple myeloma | 100/42 | 2.4 (2.0–2.9) | 40/39 | 1.0 (0.7–1.4) | 516/495 | 1.0 (1.0–1.1) | 656/576 | 1.14 (1.05–1.23) |
| Leukaemiad | 54/28 | 1.9 (1.5–2.5) | 30/26 | 1.2 (0.8–1.7) | 275/317 | 0.9 (0.8–1.0) | 359/371 | 1.0 (0.9–1.1) |
| Cancers with no associations | ||||||||
| Ovary | 22/16 | 1.3 (0.8–2.0) | 14/15 | 0.9 (0.5–1.5) | 171/187 | 0.9 (0.8–1.1) | 207/218 | 1.0 (0.8–1.1) |
| Melanoma | 41/33 | 1.3 (0.90–1.7) | 37/31 | 1.2 (0.8–1.7) | 438/447 | 1.0 (0.9–1.1) | 516/510 | 1.0 (0.9–1.1) |
| Basal cell carcinoma of the skin | 258/262 | 1.0 (0.9–1.1) | 228/245 | 0.9 (0.8–1.1) | 3271/3412 | 1.0 (0.9–1.0) | 3757/3921 | 1.0 (0.9–1.0) |
Data are standardised incidence ratios (SIRs) with 95% confidence intervals (CI)
aOnly cancer sites with total number of outcomes above 50 is presented in this table
bPharynx includes cancers in the nasal part of the pharynx, pharyngeal tonsil, the pharyngeal cavity, and other parts of pharynx (unspecified, Waldeyer’s ring, and overlapping lesions of the lip, oral cavity, and pharynx)
cColorectal cancer includes cancers in the rectum, caecum, anus, appendix, ascending colon hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, and colon unspecified
dLeukaemia includes: monocytic leukaemia, acute myeloid leukaemia (acute myeloid leukaemia with multilineage dysplasia and myeloid leukaemia, unspecified), and other leukaemias of specified cell type. Lymphoid leukaemia: acute leukaemias, chronic lymphocytic leukaemia of B-cell type, prolymphocytic leukaemia of B-cell type, hairy-cell leukaemia, adult T-cell lymphoma/leukaemia, prolymphocytic leukaemia of T-cell type, other lymphoid leukaemia, mature B-cell leukaemia Burkitt-type, and lymphoid leukaemia, unspecified